Carles Martínez-Romero, Ph.D.

Research Assistant Professor
carles.martinez@mssm.edu

 

 

 

 

 

Research Interests

My contribution as a Research Assistant Professor in the García-Sastre laboratory and in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai encompasses several roles and duties, including basic and translational RNA virus research (Influenza virus and SARS-CoV-2), scientific coordination of animal protocol submission to the Institutional Animal Care and Use Committee (IACUC), as well as team leadership in biocontainment training and occupational health compliance.

I am currently participating in different research projects involving SARS-CoV-2, which include a) adaptation of different SARS-CoV-2 viral stocks using several mouse strains, b) immunization experiments and SARS-CoV-2 antiviral compound testing using the golden Syrian hamster model, c) generation of plasmid, viral stocks and reagents for our lab and for collaborators. I am also participating in other non-SARS-CoV-2 projects, which include Influenza A virus-related studies to ascertain new aspects of the interaction between the virus and the host.

Moreover, I am the lead coordinator of animal protocol submissions in the laboratory, managing >30 currently active IACUC submissions, actively maintaining annual and triennial reviews up to date, as well as providing training guidance and institutional compliance support to the research team. I also support the Biosafety Level 3 containment unit management, providing materials and equipment for the scientific needs. I also lead the Standard Operating Procedures submission process in close collaboration with the Institutional Biosafety Committee (IBC), as well as coordinating Occupational Health & Safety (OHS) compliance of all team members with Employee Health & Safety (EHS).

Finally, I currently serve as a full member of the Institutional Animal Care And Use Committee (IACUC) board, participating in biweekly review meetings, overseeing the use of small and large animal models in the Mount Sinai network, participating in the review process of animal protocol submissions with my scientific feedback while being in close communication with CCMS directors and veterinarians.

 

Notable Publications
White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E, Jangra S, Uccellini MB, Rathnasinghe R, Coughlan L, Martínez-Romero C, Batra J, Rojc A, Bouhaddou M, Fabius JM, Obernier K, Dejosez M, Guillén MJ, Losada A, Avilés P, Schotsaert M, Zwaka T, Vignuzzi M, Shokat KM, Krogan NJ, García-Sastre A. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science 25 Jan 2021: eabf4058 doi: 10.1126/science.abf4058.

Rathnasinghe R, Jangra S, Čupić A, Martínez-Romero C, Mulder LCF, Kehrer T, Yildiz S, Choi A, Mena I, De Vrieze J, Aslam S, Stadlbauer D, Meekins DA, McDowell CD, Balaraman V, Richt JA, De Geest BG, Miorin L, PVI study group, Krammer F, Simon V, García-Sastre A, Schotsaert M. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv doi: 10.1101/2021.01.19.21249592.

Martínez-Romero C*, Muñoz-Moreno R*, García-Sastre A. Induction and Evasion of Type-I Interferon Responses during Influenza A Virus Infection. Cold Spring Harb Perspect Med. 2020 Jul 6:a038414. doi: 10.1101/cshperspect.a038414.

Muñoz-Moreno R*, Martínez-Romero C*, Blanco-Melo D, Forst C, Nachbagauer R, Benitez A, Mena I, Aslam S, Balasubramaniam V, Lee I, Panis M, Ayllón J, Sachs D, Park MS, Krammer F, tenOever B and García-Sastre A. Viral Fitness Landscapes in Diverse Host Species Reveal Multiple Evolutionary Lines for the NS1 Gene of Influenza A Viruses. Cell Rep. 2019 Dec 17;29(12):3997-4009.e5. doi: 10.1016/j.celrep.2019.11.070.

 Martínez-Romero C*, Kouznetsova J*, Sun W*, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W, García-Sastre A. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect. 2014 Dec;3(12):e84. doi: 10.1038/emi.2014.88. Epub 2014 Dec 17.